Download PDF
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2021; 81(11): 1217-1223
DOI: 10.1055/a-1533-1651
GebFra Science
Review

Risk of Recurrence in Uterine Leiomyoma with Bizarre Nuclei: a Systematic Review and Meta-Analysis

Gefahr eines Rezidivs bei uterinem Leiomyom mit bizarrem Zellkern: eine systematische Überprüfung und Metaanalyse
Antonio Travaglino
1   Anatomic Pathology Unit, Department of Advanced Biomedical Sciences, School of Medicine, University of Naples Federico II, Naples, Italy
,
Antonio Raffone
2   Gynecology and Obstetrics Unit, Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy
3   Division of Gynaecology and Human Reproduction Physiopathology, Department of Medical and Surgical Sciences (DIMEC), IRCCS Azienda Ospedaliero-Univeristaria di Bologna, S. Orsola Hospital, University of Bologna, Bologna, Italy
,
Angela Santoro
4   Pathology Unit, Department of Woman and Child Health, Agostino Gemelli University Polyclinic, Catholic University of the Sacred Heart, Rome, Italy
,
Diego Raimondo
3   Division of Gynaecology and Human Reproduction Physiopathology, Department of Medical and Surgical Sciences (DIMEC), IRCCS Azienda Ospedaliero-Univeristaria di Bologna, S. Orsola Hospital, University of Bologna, Bologna, Italy
,
Francesco Paolo Improda
2   Gynecology and Obstetrics Unit, Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy
,
Federica Cariati
5   CEINGE-Biotecnologie Avanzate, Naples, Italy
6   Fertility Unit, Maternal-Child Department, AOU Policlinico Federico II, Naples, Italy
,
Margot De Marco
7   Department of Medicine, Surgery and Odontology Schola Medica Salernitana, University of Salerno, Baronissi, SA, Italy
,
Paolo Casadio
3   Division of Gynaecology and Human Reproduction Physiopathology, Department of Medical and Surgical Sciences (DIMEC), IRCCS Azienda Ospedaliero-Univeristaria di Bologna, S. Orsola Hospital, University of Bologna, Bologna, Italy
,
Renato Seracchioli
3   Division of Gynaecology and Human Reproduction Physiopathology, Department of Medical and Surgical Sciences (DIMEC), IRCCS Azienda Ospedaliero-Univeristaria di Bologna, S. Orsola Hospital, University of Bologna, Bologna, Italy
,
Fulvio Zullo
2   Gynecology and Obstetrics Unit, Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy
,
Luigi Insabato
1   Anatomic Pathology Unit, Department of Advanced Biomedical Sciences, School of Medicine, University of Naples Federico II, Naples, Italy
,
Gian Franco Zannoni
3   Division of Gynaecology and Human Reproduction Physiopathology, Department of Medical and Surgical Sciences (DIMEC), IRCCS Azienda Ospedaliero-Univeristaria di Bologna, S. Orsola Hospital, University of Bologna, Bologna, Italy
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objective Leiomyoma with bizarre nuclei (LBN) is a variant of uterine leiomyoma, which has replaced the previous category of “atypical leiomyoma” and must be distinguished from smooth muscle tumors of uncertain malignant potential (STUMP). However, previously published series of “atypical leiomyoma” might have included both LBN and STUMP, due to the lack of strict diagnostic criteria. Based on such hypothesis, we aimed to define the risk of recurrence in LBN.

Study Design A systematic review and meta-analysis was performed by searching 4 electronic databases for all studies assessing the outcome of patients with “atypical leiomyoma” or LBN. The pooled absolute risk of recurrence was calculated. The included studies were subdivided into two subgroups based on the criteria used: “LBN + STUMP” or “LBN-only”.

Results Twelve studies with 433 patients were included. The pooled risk of recurrence was 5.5% overall. The funnel plot showed two cluster of studies which superimposed to the two subgroups. In the LBN + STUMP cluster/subgroup, the pooled risk of recurrence was 7.7%. In the LBN-only cluster/subgroup, the pooled risk of recurrence was 1.9%. Statistical heterogeneity was null in all analyses.

Conclusion Our results show a risk of recurrence of 1.9% for LBN; higher recurrence rates in older studies are likely due to the inclusion of STUMPs.

Zusammenfassung

Zielsetzung Leiomyom mit bizarrem Zellkern (LBN) ist eine Variante von uterinen Leiomyomen, welche die frühere Kategorie „atypisches Leiomyom“ ersetzt; sie sollte von glattmuskulären Tumoren mit unsicherem malignen Potenzial (STUMP) unterschieden werden. Weil aber strenge diagnostischen Kritierien bei früheren Studien fehlten, kann es sein, dass früher veröffentlichte Serien von atypischen Leiomyomen sowohl LBN als auch STUMP umfassen. Basierend auf dieser Hypothese war das Ziel unserer Studie, die Gefahr eines Rezidivs bei LBN zu definieren.

Studiendesign Eine systematische Überprüfung und eine Metaanalyse wurden durchgeführt. Hierzu wurden 4 elektronische Datenbanken nach Studien durchsucht, die das Outcome von Patientinnen mit atypischen Leiomyomen bzw. LBN evaluierten. Das gepoolte absolute Risiko eines Rezidivs wurde berechnet. Die eingeschlossenen Studien wurden in 2 Untergruppen unterteilt: eine LBN + STUMP-Gruppe und eine Nur-LBN-Gruppe.

Ergebnisse Zwölf Studien mit insgesamt 433 Patientinnen wurden gefunden und evaluiert. Das gepoolte Risiko eines Rezidivs betrug insgesamt 5,5%. Der Funnel Plot zeigte 2 Cluster von Studien, die sich mit den 2 Untergruppen überlagerten. In der LBN + STUMP-Cluster/Untergruppe betrug das gepoolte Risiko für ein Rezidiv 7,7%. In der Nur-LBN-Cluster/Untergruppe betrug das gepoolte Risiko eines Rezidivs dagegen 1,9%. Die statistische Heterogenität betrug bei allen Analysen null.

Schlussfolgerung Unsere Ergebnisse zeigen, dass die Gefahr eines Rezidivs bei LBN 1,9% beträgt; die höheren Rezidivraten in älteren Studien beruhen wahrscheinlich auf dem Einschluss von STUMP.

Key words

prognosis - diagnosis - sarcoma - myoma - leiomyoma - myomata

Schlüsselwörter

Prognose - Diagnose - Sarkom - Myom - Leiomyom - Myome

Supporting Information



Publication History

Received: 26 March 2021

Accepted: 18 June 2021

Article published online:
04 November 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Mazzei P, Piccolo A, Nugnes L. et al. Metabolic profile of intact tissue from uterine leiomyomas using high-resolution magic-angle-spinning 1H NMR spectroscopy. NMR Biomed 2010; 23: 1137-1145
    CrossrefPubMedGoogle Scholar
  • 2 De Falco M, Staibano S, Mascolo M. et al. Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes. Eur J Obstet Gynecol Reprod Biol 2009; 144: 44-47
    CrossrefPubMedGoogle Scholar
  • 3 De Falco M, Staibano S, DʼArmiento FP. et al. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor. J Soc Gynecol Investig 2006; 13: 297-303
    CrossrefPubMedGoogle Scholar
  • 4 Denschlag D, Ackermann S, Battista MJ. et al. Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019). Geburtshilfe Frauenheilkd 2019; 79: 1043-1060
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 WHO Classification of Tumours Editorial Board. Female Genital Tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed., vol. 4)
    Google Scholar
  • 6 Gadducci A, Zannoni GF. Uterine smooth muscle tumors of unknown malignant potential: A challenging question. Gynecol Oncol 2019; 154: 631-637
    CrossrefPubMedGoogle Scholar
  • 7 Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994; 18: 535-558
    CrossrefPubMedGoogle Scholar
  • 8 Downes KA, Hart WR. Bizarre leiomyomas of the uterus: a comprehensive pathologic study of 24 cases with long-term follow-up. Am J Surg Pathol 1997; 21: 1261-1270
    CrossrefPubMedGoogle Scholar
  • 9 Sung CO, Ahn G, Song SY. et al. Atypical leiomyomas of the uterus with long-term follow-up after myomectomy with immunohistochemical analysis for p 16INK4A, p 53, Ki-67, estrogen receptors, and progesterone receptors. Int J Gynecol Pathol 2009; 28: 529-534
    CrossrefPubMedGoogle Scholar
  • 10 Ly A, Mills AM, McKenney JK. et al. Atypical leiomyomas of the uterus: a clinicopathologic study of 51 cases. Am J Surg Pathol 2013; 37: 643-649
    CrossrefPubMedGoogle Scholar
  • 11 Croce S, Young RH, Oliva E. Uterine leiomyomas with bizarre nuclei: a clinicopathologic study of 59 cases. Am J Surg Pathol 2014; 38: 1330-1339
    CrossrefPubMedGoogle Scholar
  • 12 Liang Y, Zhang X, Chen X. et al. Diagnostic value of progesterone receptor, p 16, p 53 and pHH3 expression in uterine atypical leiomyoma. Int J Clin Exp Pathol 2015; 8: 7196-7202
    PubMedGoogle Scholar
  • 13 Kalogiannidis I, Stavrakis T, Dagklis T. et al. A clinicopathological study of atypical leiomyomas: Benign variant leiomyoma or smooth-muscle tumor of uncertain malignant potential. Oncol Lett 2016; 11: 1425-1428
    CrossrefPubMedGoogle Scholar
  • 14 Ubago JM, Zhang Q, Kim JJ. et al. Two Subtypes of Atypical Leiomyoma: Clinical, Histologic, and Molecular Analysis. Am J Surg Pathol 2016; 40: 923-933
    CrossrefPubMedGoogle Scholar
  • 15 Bennett JA, Weigelt B, Chiang S. et al. Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases. Mod Pathol 2017; 30: 1476-1488
    CrossrefPubMedGoogle Scholar
  • 16 Kefeli M, Caliskan S, Kurtoglu E. et al. Leiomyoma With Bizarre Nuclei: Clinical and Pathologic Features of 30 Patients. Int J Gynecol Pathol 2018; 37: 379-387
    CrossrefPubMedGoogle Scholar
  • 17 Gregová M, Hojný J, Němejcová K. et al. Leiomyoma with Bizarre Nuclei: a Study of 108 Cases Focusing on Clinicopathological Features, Morphology, and Fumarate Hydratase Alterations. Pathol Oncol Res 2019; DOI: 10.1007/s12253-019-00739-5.
    CrossrefPubMedGoogle Scholar
  • 18 Chow KL, Tse KY, Cheung CL. et al. The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study. Histopathology 2017; 70: 746-755
    CrossrefPubMedGoogle Scholar
  • 19 Atkins KA, Arronte N, Darus CJ. et al. The Use of p 16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol 2008; 32: 98-102
    CrossrefPubMedGoogle Scholar
  • 20 Ip PP, Cheung AN, Clement PB. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. Am J Surg Pathol 2009; 33: 992-1005
    CrossrefPubMedGoogle Scholar
  • 21 Veras E, Malpica A, Deavers MT. et al. Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study. Int J Gynecol Pathol 2009; 28: 316-321
    CrossrefPubMedGoogle Scholar
  • 22 Dańska-Bidzińska A, Bakuła-Zalewska E, Nasierowska-Guttmejer A. et al. [Smooth muscle tumor of uncertain malignant potential (STUMP)–clinico-pathomorphological analysis of the cases and literature review]. Ginekol Pol 2012; 83: 412-416
    PubMedGoogle Scholar
  • 23 DallʼAsta A, Gizzo S, Musarò A. et al. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): pathology, follow-up and recurrence. Int J Clin Exp Pathol 2014; 7: 8136-8142
    PubMedGoogle Scholar
  • 24 Croce S, Ribeiro A, Brulard C. et al. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions. Mod Pathol 2015; 28: 1001-1010
    CrossrefPubMedGoogle Scholar
  • 25 Slatter TL, Hsia H, Samaranayaka A. et al. Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma. J Pathol Clin Res 2015; 1: 95-105
    CrossrefPubMedGoogle Scholar
  • 26 Bacanakgil BH, Deveci M, Karabuk E. et al. Uterine Smooth Muscle Tumor of Uncertain Malignant Potential: Clinicopathologic-Sonographic Characteristics, Follow-Up and Recurrence. World J Oncol 2017; 8: 76-80
    CrossrefPubMedGoogle Scholar
  • 27 Esposito NN, Hunt JL, Bakker A. et al. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors. Am J Surg Pathol 2006; 30: 97-103
    CrossrefPubMedGoogle Scholar
  • 28 Basaran D, Usubutun A, Salman MC. et al. The Clinicopathological Study of 21 Cases With Uterine Smooth Muscle Tumors of Uncertain Malignant Potential: Centralized Review Can Purify the Diagnosis. Int J Gynecol Cancer 2018; 28: 233-240
    CrossrefPubMedGoogle Scholar
  • 29 Gupta M, Laury AL, Nucci MR. et al. Predictors of adverse outcome in uterine smooth muscle tumours of uncertain malignant potential (STUMP): a clinicopathological analysis of 22 cases with a proposal for the inclusion of additional histological parameters. Histopathology 2018; 73: 284-298
    CrossrefPubMedGoogle Scholar
  • 30 Ha HI, Choi MC, Heo JH. et al. A clinicopathologic review and obstetric outcome of uterine smooth muscle tumor of uncertain malignant potential (STUMP) in a single institution. Eur J Obstet Gynecol Reprod Biol 2018; 228: 1-5
    CrossrefPubMedGoogle Scholar
  • 31 Karataşlı V, Çakır İ, Ayaz D. et al. Clinicopathologic evaluation of uterine smooth muscle tumors of uncertain malignant potential (STUMP): A single center experience. J Gynecol Obstet Hum Reprod 2019; 48: 637-642
    CrossrefPubMedGoogle Scholar
  • 32 Travaglino A, Raffone A, Saccone G. et al. Congruence Between 1994 WHO Classification of Endometrial Hyperplasia and Endometrial Intraepithelial Neoplasia System. Am J Clin Pathol 2020; 153: 40-48
    CrossrefPubMedGoogle Scholar
  • 33 Travaglino A, Raffone A, Saccone G. et al. Nuclear expression of β-catenin in endometrial hyperplasia as marker of premalignancy. APMIS 2019; 127: 699-709
    CrossrefPubMedGoogle Scholar
  • 34 Moher D, Shamseer L, Clarke M. et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1
    CrossrefPubMedGoogle Scholar
  • 35 Whiting PF, Rutjes AW, Westwood ME. et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-536
    CrossrefPubMedGoogle Scholar
  • 36 Travaglino A, Raffone A, Mascolo M. et al. TCGA Molecular Subgroups in Endometrial Undifferentiated/Dedifferentiated Carcinoma. Pathol Oncol Res 2020; 26: 1411-1416
    CrossrefPubMedGoogle Scholar
  • 37 Travaglino A, Raffone A, Gencarelli A. et al. Stanford parameters stratify the risk of recurrence in gynecologic smooth muscle tumors of uncertain malignant potential. APMIS 2021; 129: 283-290
    CrossrefPubMedGoogle Scholar